Joon Rhee
Managing Partner at Fincadia at Fincadia Capital
New York, New York
Joon Rhee, Managing Partner at Fincadia at Fincadia Capital is an active investor based in New York, New York. This profile covers what Joon Rhee backs, at which stage, and how founders can reach out in 2026.
Joon Rhee is a Managing Partner at Fincadia Capital and Fund Manager at FCP Venture X.
- Investor type
- VC
- Stages
- SeedSeries A
- Invests in
- Fintech
- Location
- New York, New York
- Typical check
- $625K
How to reach Joon Rhee
Angels and operators like Joon Rhee reply to specific, personalized notes that show real traction, not mass blasts. Build a verified list, write a note that fits their thesis, and track replies, all on Round Funded.
Connect with Joon Rhee
About this profile
This profile is part of Round Funded, an investor database and outreach platform for founders. It covers 60,000+ active VCs, angels, family offices and accelerators with verified contacts, lets you send pitches from your own Gmail, and includes a free Data Room for your raise.
Frequently Asked Questions
What does Joon Rhee invest in?
Joon Rhee invests in Fintech, typically at Seed and Series A. Match your sector and stage, then reach out with a personalized pitch.
What stage does Joon Rhee invest at?
Joon Rhee typically invests at Seed and Series A. Lead with traction that fits the stage when you reach out.
What is Joon Rhee's typical check size?
Joon Rhee typically writes checks around $625K. Use it as a signal for whether your raise fits their stage.
How do I contact Joon Rhee?
Unlock Joon Rhee's verified email on Round Funded and send a personalized pitch. We surface only deliverable contacts so your outreach lands.
What is Round Funded?
Round Funded is an investor database and outreach platform for startup founders. It lists 60,000+ active investors with verified contacts, filtered to recent investment activity, and lets founders send personalized pitches from their own Gmail, track replies, and share a free Data Room. Round+ starts at $99 per month with a 3-day trial.